journal
MENU ▼
Read by QxMD icon Read
search

Leukemia Research Reports

journal
https://www.readbyqxmd.com/read/28331798/aspirin-and-risk-of-multiple-myeloma-in-adults-a-systematic-review-and-meta-analysis
#1
REVIEW
Shing Fung Lee, Ting Ying Ng, Frank Chi Sing Wong, Stewart Yuk Tung
Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the association between regular aspirin use and risk of multiple myeloma. Five observational studies including 332,660 adults were evaluated. The pooled estimate had a hazard ratio of 0.90 (95% confidence interval =0.58-1.39; P=0.638). Odds ratios from the two case-control studies were similar...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28275540/a-rare-breed-wild-type-braf-and-ighv-expression-in-a-29-year-old-lady-with-classical-hairy-cell-leukemia
#2
Aneesha Hossain, Hind Rafei, Amar Jariwala, Khaled El-Shami
The V600 BRAF mutation has been described as a key mutation in the pathogenesis of classical hairy cell leukemia (c-HCL) cases without expression of a mutant immunoglobulin heavy chain (IgHV). Here we present a rare case of c-HCL with neither V600 BRAF mutation nor the aforementioned IgHV variant successfully treated with cladribine and review the current literature on its use in women of childbearing age/pregnancy.
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28275539/a-case-of-acute-myeloid-leukemia-with-e6a2-bcr-abl-fusion-transcript-acquired-after-progressing-from-chronic-myelomonocytic-leukemia
#3
Jinjuan Yao, Dan Douer, Lu Wang, Maria E Arcila, Khedoudja Nafa, April Chiu
Philadelphia (Ph) chromosome is a cytogenetic hallmark of chronic myeloid leukemia (CML). Most patients with CML harbor either the e13a2 or e14a2 BCR-ABL fusion product, while a small subset of the cases expresses e1a2 or e19a2 transcripts. We report a patient with chronic myelomonocytic leukemia (CMML), initially Ph chromosome negative at presentation, with rapid disease progression to acute myeloid leukemia (AML) and appearance of Ph chromosome and BCR-ABL e6a2, a very uncommon fusion transcript. The AML was refractory to treatment with subsequent emergence and dominance of a Ph negative leukemic clone...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28229039/clofarabine-desensitization-a-case-report-leukemia-research-reports
#4
Sarah M Hayes, Justin A Wasko, Erica Dahl Warlick
We describe a relapsed AML patient who had two prior severe reactions to clofarabine involving rigors, emesis, tachycardia, hypotension, and acute kidney injury. Given previous prolonged remission achieved with clofarabine and cytarabine therapy years prior, rechallenge was undertaken upon discovery of AML relapse. We designed a desensitization protocol performed with the first dose of clofarabine, leading to successful administration of the entire clofarabine/cytarabine treatment course. From this case we show promise for clofarabine rechallenge after prior hypersensitivity reactions in patients with few treatment options for relapsed AML...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28180067/-hemophagocytic-lymphohistiocytosis-after-ebv-reactivation-and-ibrutinib-treatment-in-relapsed-refractory-chronic-lymphocytic-leukemia
#5
Maurizio Cavallari, Maria Ciccone, Simonetta Falzoni, Francesco Cavazzini, Luca Formigaro, Francesco Di Virgilio, Antonella Rotola, Gian Matteo Rigolin, Antonio Cuneo
Hemophagocytic Lymphohistiocytosis (HLH) is a rare syndrome characterized by ineffective T-cell and NK response. We report the clinical course of a patient with relapsed CLL who developed acute symptoms soon after starting ibrutinib. Hyperpyrexia, splenomegaly, hyperferritinemia, hypertriglyceridemia, cytopenias, and a typical cytokine pattern, i.e. high interleukin (IL)-6, IL10 and IL18, were consistent with a diagnosis of HLH. Coexistent Epstein Barr virus reactivation was documented. Ibrutinib-induced impairment of NK degranulation, associated with EBV reactivation and CLL-related immunodeficiency may have contributed to the development of HLH in our patient...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28066705/clinical-outcomes-of-aml-patients-treated-with-azacitidine-in-portugal-a-retrospective-multicenter-study
#6
António Almeida, Ana Rita Ferreira, Maria João Costa, Sofia Silva, Khalil Alnajjar, Isabel Bogalho, Francesca Pierdomenico, Susana Esteves, Mafalda Alpoim, Gil Braz, Emilia Cortesão, Ricardo Pinto
Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104)...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/28053856/a-primary-esophageal-malt-lymphoma-patient-with-helicobacter-pylori-infection-achieved-complete-remission-after-h-pylori-eradication-without-anti-lymphoma-treatment
#7
Keiichi Moriya, Hideto Tamura, Kyoko Nakamura, Masaru Hosone, Koiti Inokuchi
Primary esophageal lymphoma is an extremely rare disease. We report a 76-year-old woman with esophageal lymphoma who achieved remission after Helicobacter pylori (HP) eradication. Esophagogastroduodenoscopy (EGD) revealed a mass in the lower esophagus, and she was diagnosed with stage IE mucosa-associated lymphoid tissue (MALT) lymphoma. She rejected any anti-lymphoma treatment except for HP eradication. Follow-up EGD demonstrated the disappearance of the esophageal MALT lymphoma 2 months after HP eradication, and she remained in remission for more than 3 years...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/27981027/renal-cell-carcinoma-and-hematological-malignancies
#8
Irfan Yavasoglu, Gokhan Sargin
No abstract text is available yet for this article.
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/27924280/the-role-of-the-exon-13-g571s-jak2-mutation-in-myeloproliferative-neoplasms
#9
Burak Bahar, Kevin Barton, Ameet R Kini
The exon 14 JAK2 V617F mutation has been well established as a driver mutation in polycythemia vera (PV) and other myeloproliferative neoplasms. JAK2 exon 12 mutations have also been implicated in PV, although patients with these mutations may show isolated erythrocytosis. Recently additional JAK2point mutations have been described-all in regions encoding the pseudokinase domain that regulates the tyrosine kinase activity of JAK2. We present a case of a patient with erythrocytosis and an exon 13 G571S mutation, and discuss the putative role of this mutation in myeloproliferative neoplasms...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27812500/an-etv6-abl1-fusion-in-a-patient-with-chronic-myeloproliferative-neoplasm-initial-response-to-imatinib-followed-by-rapid-transformation-into-all
#10
Purvi M Kakadia, Ralf Schmidmaier, Andreas Völkl, Irene Schneider, Natalia Huk, Stephanie Schneider, Gerda Panzner, Ulrike Neidel, Barbara Fritz, Karsten Spiekermann, Stefan K Bohlander
We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be confirmed. The patient was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient expired...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27752467/novel-therapeutic-options-in-acute-myeloid-leukemia
#11
REVIEW
Michael Medinger, Claudia Lengerke, Jakob Passweg
Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence is increasing as the population ages. Cytogenetic anomalies and mutation testing remain important prognostic tools for tailoring treatment after induction therapy. Despite major advances in understanding the genetic landscape of AML and its impact on the pathophysiology and biology of the disease, as well as the rapid development of new drugs, standard treatment options have not experienced major changes during the past three decades...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27656412/involvement-of-cd147-on-multidrug-resistance-through-the-regulation-of-p-glycoprotein-expression-in-k562-adr-leukemic-cell-line
#12
Aoranit Somno, Songyot Anuchapreeda, Nuttapol Chruewkamlow, Supansa Pata, Watchara Kasinrerk, Sawitree Chiampanichayakul
The relationship between P-gp and CD147 in the regulation of MDR in leukemic cells has not been reported. This study aimed to investigate the correlation between CD147 and P-gp in the regulation of drug resistance in the K562/ADR leukemic cell line. The results showed that drug-resistant K562/ADR cells expressed significantly higher P-gp and CD147 levels than drug-free K562/ADR cells. To determine the regulatory effect of CD147 on P-gp expression, anti-CD147 antibody MEM-M6/6 significantly decreased P-gp and CD147 mRNA and protein levels...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27547725/congenital-b-lymphoblastic-leukemia-with-a-cryptic-mll-rearrangement-and-post-treatment-evolution-to-mixed-phenotype-acute-leukemia
#13
Elizabeth Moschiano, Gordana Raca, Cecilia Fu, Paul K Pattengale, Mathew J Oberley
Congenital leukemia is a rare event with a poor prognosis. We report a case of congenital leukemia with a cryptic rearrangement of MLL demonstrable only with RT-PCR. Interestingly, with treatment, the patient showed lineage plasticity of the leukemia with the development of monocytic lineage blasts after presenting with B-cell lineage blasts. This was heralded by the development of a new clonal cytogenetic abnormality. This case highlights the primitive nature of the leukemic cells in congenital leukemia, and emphasizes that RT-PCR for MLL rearrangements may identify a subset of cases which are otherwise negative by karyotyping, FISH, and chromosomal microarrays...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27489766/enhanced-international-prognostic-index-in-japanese-patients-with-diffuse-large-b-cell-lymphoma
#14
Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura
To evaluate the National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI), we analyzed 284 patients treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in our institution in Japan. Their 5-year overall survival (OS) by risk level was 80.7%, 74.8%, 55.4% and 67.5% (P=0.005); and their 5-year progression-free survival (PFS) was 76.8%, 78.6%, 63.7% and 58.3% (P=0.0722). The NCCN-IPI is a simple scale that uses conventional clinical factors, but did not reflect survival in our cohort...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27489765/a-remarkable-hematological-and-molecular-response-pattern-in-a-patient-with-polycythemia-vera-during-combination-therapy-with-simvastatin-and-alendronate
#15
Anders Lindholm Sørensen, Klaus Kallenbach, Hans Carl Hasselbalch
We report a 57-year old man with polycythemia vera, who had a remarkable hematological and molecular response during treatment with simvastatin and alendronate. The patient was treated with this combination for 56 months, and during this period the patient has been in complete hematological remission. The JAK2-V617F allele burden has dropped from 64% to sustained values below 20%, and follow-up bone marrow biopsies have revealed no change in PV features, without any regular cytoreductive treatment.
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27489764/changing-of-ikzf1-genotype-during-philadelphia-negative-precursor-b-acute-lymphoblastic-leukemia-progression-a-short-clinical-report
#16
Volha Vshyukova, Alexander Meleshko, Natalia Mihal, Olga Aleinikova
•The case demonstrated a rare event of clonal heterogeneity by IKZF1 gene status in BCRABL1- ALL.•IKZF1 deletions are secondary events in ALL caused by clonal evolution during the treatment.•It's prognostic significance could be more crucial in BCR-ABL- rather than in BCR-ABL + ALL.•IKZF1 gene alterations may be determined and proved at the genome, expression and protein level.•IKZF1 deletions are suitable for MRD detection but not stable compared to Ig/TCR rearrangement.
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27453816/a-case-of-srsf2-mutation-in-chronic-lymphocytic-leukemia
#17
Eduardo Garza, Giovanni Del Poeta, Carmen Martínez-Losada, Gianfranco Catalano, Loredana Borgia, Maria Liliana Piredda, Emiliano Fabiani, Valter Gattei, Francesco Lo-Coco, Nélida I Noguera
Chronic lymphocytic leukemia (CLL) is characterized by extremely variable clinical course indicating substantial differences in the biology of the disease. Molecular characterization provides new insights useful for treatment decision making. We report on a patient diagnosed with CLL, whose disease was characterized by episodes of rapid progression and disease stabilization, and in which a SRSF2 gene mutation was identified in the absence of other commonly known mutations of CLL. To the best of our knowledge this is the first case of SRSF2 gene mutation ever reported in CLL...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27453815/chronic-lymphocytic-lymphoma-and-concomitant-renal-cell-carcinoma-clear-cell-type-review-of-the-literature
#18
Burak Uz, Ilhan Dolasik, Ozlem Ucer, Adile Ferda Dagli, Sercan Simsek
In the present report, a 73 years-old male patient who developed clear cell type renal cell carcinoma (RCC) 5 years after the diagnosis of chronic lymphocytic lymphoma (CLL) and plausible explanations for this association were discussed by the authors. The incidence of CLL and RCC occurring in the same patient is higher than that expected in the general population. Various explicative hypotheses of this concurrence include treatment-related development of a second malignancy, immunomodulatory mechanisms, viral aetiology, cytokine (interleukin 6) release from a tumor, and common genetic mutations...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27408788/acute-myeloid-leukemia-in-the-older-adults
#19
REVIEW
Antonio M Almeida, Fernando Ramos
AML is an aggressive hematological malignancy with highest incidence in the older adults. The adverse features of AML in the elderly, and the frailties and comorbidities frequently present in them, make their management a particularly difficult therapeutic challenge. In this context, it is important to assess carefully patient- as well as disease-associated prognostic features with validated tools. The fittest patients should be considered for curative therapy, such as bone marrow transplantation, whereas low intensity options may be more appropriate for frail patients...
2016: Leukemia Research Reports
https://www.readbyqxmd.com/read/27298759/genomic-imbalances-in-peripheral-blood-confirm-the-diagnosis-of-myelodysplastic-syndrome-in-a-patient-presenting-with-non-immune-hemolytic-anemia
#20
Mohammad Faizan Zahid, Nadia Khan, Jianming Pei, Joseph R Testa, Essel Dulaimi
Myelodysplastic syndrome (MDS) is a clonal stem-cell disorder characterized by dyshematopoiesis. We report a patient who presented with cytopenias and microangiopathic hemolytic anemia. Chromosome microarray analysis (CMA), using single nucleotide polymorphism arrays, on peripheral blood revealed genomic imbalances indicative of MDS, which was confirmed by bone marrow examination. This report highlights the importance of suspecting MDS in patients with cytopenias and microangiopathic hemolytic anemia. CMA of peripheral blood may assist in the preliminary diagnosis of MDS, representing a comparatively less invasive diagnostic procedure and may aid bone marrow evaluation when an aspirate sample is insufficient for conventional cytogenetic analysis...
2016: Leukemia Research Reports
journal
journal
47893
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"